A UK-BASED pharma business has appointed a director of corporate development as the company eyes growth in international markets.
Kelso Pharma has appointed John Rooper to the role, who has previously worked at Ernst and Young in a senior mergers and acquisitions (M&A) role and as associate director M&A at Advanz Pharma.
Kelso Pharma Group hope that John will play a role in the company’s ambitions for international expansion as it attempts to identify growth opportunities across a number of regions.
The company is growing through a blend of product and company acquisitions, partnerships, which aims to spark growth internationally.
The appointment comes as Kelso Pharma acquired the Italian company Velit Biopharma at the start of this year.
Dr Tom Stratford, Kelso Pharma CEO, said: “It’s a pleasure to welcome John to the Kelso Pharma team.
“John brings considerable experience in the life sciences sector and his extensive involvement in M&A will be invaluable as we continue to grow internationally.
“At Kelso Pharma, we have ambitious goals to bring in more products and continue to build our infrastructure across Europe and John joining the business is an important step on that journey.”
John Rooper, director of corporate development, said: “I’m thrilled to be joining the Kelso Pharma team.
“The business is ambitious, innovative, people focused and committed to growth on an international scale and I’m excited to be involved and play a big part in the team achieving its goals.”
